Nanobiotix S.A. (NBTX)

NASDAQ: NBTX · IEX Real-Time Price · USD
4.41
-0.25 (-5.36%)
At close: Aug 18, 2022 9:42 AM
4.28
-0.13 (-2.95%)
After-hours: Aug 18, 2022 4:00 PM EDT
-5.36%
Market Cap 153.80M
Revenue (ttm) 3.01M
Net Income (ttm) -53.41M
Shares Out 34.88M
EPS (ttm) -1.42
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 160
Open 4.69
Previous Close 4.66
Day's Range 4.41 - 4.41
52-Week Range 2.32 - 14.14
Beta 2.25
Analysts Buy
Price Target 19.57 (+343.8%)
Earnings Date May 18, 2022

About NBTX

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thail... [Read more...]

Industry Biotechnology
IPO Date Dec 11, 2020
CEO Laurent Levy
Employees 100
Stock Exchange NASDAQ
Ticker Symbol NBTX
Full Company Profile

Financial Performance

In 2021, Nanobiotix's revenue was 2.65 million, an increase of 5.37% compared to the previous year's 2.51 million. Losses were -47.00 million, 39.9% more than in 2020.

Financial numbers in EUR Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for NBTX stock is "Buy." The 12-month stock price forecast is 19.57, which is an increase of 343.76% from the latest price.

Price Target
$19.57
(343.76% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Half-year Report on the Nanobiotix Liquidity Contract With Gilbert Dupont

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #NBTXNews--Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company”), a late-clinical stage biotechnology company pioneering phys...

NANOBIOTIX: New Data Featuring NBTXR3 Plus Chemoradiation and in the Preoperative Setting Support Broad Applicability...

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext : NANO –– Nasdaq: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approache...

NANOBIOTIX Annual Shareholders' General Meeting to Be Held on June 23, 2022

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based approaches ...

CORRECTING and REPLACING: NANOBIOTIX Provides First Quarter Operational and Financial Update

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: This replaces the announcement made at 4:40PM EDT/20:40 CEST on May 18 due to the following correction: Updated date in "First Quarter Operati...

NANOBIOTIX Provides First Quarter Operational and Financial Update

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the "Company"), a late-clinical stage biotechnology company pioneering physics-based approaches to...

NANOBIOTIX to Present During the Jefferies Healthcare Conference in June 2022

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approache...

NANOBIOTIX to Participate in Two Upcoming Investor Conferences

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the "Company"), a clinical-stage biotechnology company pioneering physics-based approaches to ex...

7 Biotech Stocks With Key Catalysts for May

The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns. The post 7 Biotech Stocks With Key Catalysts for May appeared first on InvestorP...

NANOBIOTIX to Announce First Quarter 2022 Financial Results on May 18, 2022

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based approaches ...

New Data Featuring NANOBIOTIX Lead Product Candidate NBTXR3 to Be Presented at the 2022 ASCO Annual Meeting

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to...

NANOBOTIX: New Preclinical Immunotherapy Data Show Boosted Anti-Tumor Immune Activation via Triple Blockade of PD-1, ...

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a clinical-stage biotechnology company pioneering physics-based approaches to e...

NANOBIOTIX Announces Filing of the 2021 Universal Registration Document and the 2021 Annual Report on Form 20-F

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based approaches ...

NANOBIOTIX Provides Business Update and Reports Full Year 2021 Financial Results

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches ...

NANOBIOTIX to Announce Full Year 2021 Financial Results on March 30, 2022

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--NANOBIOTIX TO ANNOUNCE FULL YEAR 2021 FINANCIAL RESULTS ON MARCH 30, 2022.

Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment...

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based approaches ...

NANOBIOTIX Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3...

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company'') (Paris:NANO) (NASDAQ:NBTX), a late-stage clinical biotechnology company pioneerin...

NANOBIOTIX Provides Corporate Update and Highlights Key 2022 Milestone Targets

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #ASCO--Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-b...

NANOBIOTIX Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head an...

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX – the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to...

Nanobiotix Announces Participation at Three Virtual Investor Conferences in January 2022

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches ...

NANOBIOTIX to Present at the 4th Annual Evercore ISI HealthCONx Conference

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company'') (Paris:NANO) (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneerin...

NANOBIOTIX Announces New Preclinical Data Highlighting NBTXR3 Immune Priming and Checkpoint Inhibitor Combination

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the "Company"), a late-stage clinical biotechnology company pioneering physics-based approaches to...

NANOBIOTIX to Participate in a Fireside Chat at the Jefferies London Healthcare Conference

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches ...

NANOBIOTIX Announces 18.1 Month Median Overall Survival for 41 Evaluable Elderly and Frail Patients With HNSCC in Pha...

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based approaches ...

NANOBIOTIX Provides Third Quarter Operational and Financial Update

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches ...

NANOBIOTIX to Present First Survival Data From Priority Head and Neck Cancer Program Among Five Presentations at the ...

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based approaches ...